Singular Genomics announces closing of acquisition by Deerfield Managment

Singular Genomics (OMIC) Systems announced the closing of its acquisition by an affiliate of Deerfield Management Company. On December 23, Singular Genomics announced that Deerfield had signed a definitive agreement to acquire all of the outstanding shares of Singular Genomics common stock not currently owned by Deerfield for $20.00 per share in cash. Following the satisfaction of customary conditions, including a vote of the holders of Singular Genomics’ common stock to approve the transaction, which occurred on February 19, 2025, the transaction has now closed. Effective as of closing, Singular Genomics now operates as a private company, which the Singular Board of Directors believes will provide the Company with greater flexibility to continue advancing its business strategy. Trading of Singular Genomics’ common stock has been suspended on Nasdaq and Singular Genomics has requested that its common stock be delisted from Nasdaq . Pursuant to the transaction, Josh Stahl has been appointed to lead Singular Genomics as CEO and will join the company’s Board of Directors. Jason Myers will also join the Board. Drew Spaventa, co-founder of Singular Genomics and the company’s previous CEO and Chairman, will continue to serve on the Board and assume an additional role as special advisor to the CEO.